Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer

Journal of Managed Care Pharmacy

Volumn 16, Issue 9, 2010, Pages 693-702

  Barlev, Arie ^a   Song, Xue ^d   Ivanov, Boris ^e   Setty, Vidya ^b   Chung, Karen ^c  

^a Amgen   (United States)

^b Global Medical Writing   (United States)

^c AMGEN INC   (United States)

^d Research Leader   (United States)

^e THOMSON REUTERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; DATA BASE; FEMALE; HEALTH CARE PLANNING; HEALTH INSURANCE; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTIPLE MYELOMA; ORTHOPEDIC SURGERY; PATHOLOGIC FRACTURE; PATIENT SELECTION; PROSTATE CANCER; RISK ASSESSMENT; SPINAL CORD COMPRESSION;

EID: 78649502301     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.9.693     Document Type: Article

References (24)

1. Fidler IJ, Kim SJ, Langley RR. The role of the organ microenvironment in the biology and therapy of cancer metastasis. J Cell Biochem. 2007;101(4):927-36.
2. Langley RR, Fidler IJ. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev. 2007;28(3):297-321. Available at: http://edrv.endojournals.org/cgi/reprint/28/3/297.pdf. Accessed October 8, 2010.
3. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655-64.
4. Berruti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol. 2000;164(4):1248-53.
5. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000;88(12 Suppl):2989-94. Available at: http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(20000615)88:12%2B%3C2989::AIDCNCR14%3E3.0.CO;2-Q/pdf. Accessed October 8, 2010.
6. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s-6249s. Available at: http://clincancerres.aacrjournals.org/content/12/20/6243s.full.pdf. Accessed October 8, 2010.
7. Trinkaus M, Simmons C, Myers J, Dranatisaris G, Clemons M. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer. 2010;18(2):197-203.
8. Coleman RE, Guise TA, Lipton A, et al. Advancing treatment for meta-static bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res. 2008;14(20):6387-95. Available at: http://clin-cancerres.aacrjournals.org/content/14/20/6387.full.pdf. Accessed October 8, 2010.
9. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88(5):1082-90. Available at: http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(20000301)88:5%3C1082::AID-CNCR20%3E3.0.CO;2-Z/pdf. Accessed October 8, 2010.
10. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-68. Available at: http://jnci.oxfordjournals.org/content/94/19/1458.full.pdf. Accessed October 8, 2010.
11. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-Available at: http://jnci.oxfordjournals.org/content/96/11/879.full.pdf. Accessed October 8, 2010.
12. Vogel CL, Yanagihara RH, Wood AJ, et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist. 2004;9(6):687-95. Available at: http://theoncologist.alphamedpress.org/cgi/reprint/9/6/687. Accessed October 8, 2010.
13. American Cancer Society. Cancer facts and figures 2007. Atlanta: American Cancer Society; 2007. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/caff2007pwsecuredpdf.pdf. Accessed October 8, 2010.
14. Chirgwin JM, Guise TA. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. J Cell Biochem. 2007;102(6):1333-42.
15. Novartis Pharmaceuticals Corporation. Zometa (zoledronic acid) prescribing information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf. Accessed October 8, 2010.
16. Henry D, Von Moos RAF, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Cancer. 2009;7(3):11 [Abstract 20LBA]. Poster presented at: Joint 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology; September 20-24, 2009; Berlin, Germany.
17. Santini D, Fratto ME, Vincenzi B, et al. Denosumab: the era of targeted therapies in bone metastatic diseases. Curr Cancer Drug Targets. 2009;9(7):834-42.
18. Stopeck A, Body J, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer. 2009;7(3):2 (Abstract 2LBA). Poster presented at: Joint 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology; September 20-24, 2009; Berlin, Germany.
19. Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care. 2008;14(5):317-22. Available at: http://www.ajmc.com/media/pdf/AJMC_08may_Lage317to322.pdf. Accessed October 8, 2010.
20. Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol. 2006;4(7):341-47.
21. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res. 2003;9(7):2394-99. Available at: http://clincancerres.aacrjournals.org/content/9/7/2394.full.pdf+html. Accessed October 12, 2010.
22. U.S. Department of Labor, Bureau of Labor Statistics. Measuring price change for medical care in the CPI. Updated April 12, 2010. Available at: http://www.bls.gov/cpi/cpifact4.htm. Accessed October 8, 2010.
23. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York: Chapman & Hall; 1993.
24. Surveillance Epidemiology and End Results. Table 1.11: Median age of cancer patients at diagnosis, 2003-2007, by primary cancer site, race and sex. SEER Cancer Statistics Review 1975-2007. National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.11_2pgs.pdf. Accessed October 8, 2010.